These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26064479)

  • 1. Promiscuity progression of bioactive compounds over time.
    Hu Y; Jasial S; Bajorath J
    F1000Res; 2015; 4(Chem Inf Sci):118. PubMed ID: 26064479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the Degree of Promiscuity of Extensively Assayed Compounds.
    Jasial S; Hu Y; Bajorath J
    PLoS One; 2016; 11(4):e0153873. PubMed ID: 27082988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing Promiscuity at the Level of Active Compounds and Targets.
    Bajorath J
    Mol Inform; 2016 Dec; 35(11-12):583-587. PubMed ID: 27870240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data.
    Hu Y; Bajorath J
    AAPS J; 2013 Jul; 15(3):808-15. PubMed ID: 23605807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyzing compound activity records and promiscuity degrees in light of publication statistics.
    Hu Y; Bajorath J
    F1000Res; 2016; 5():. PubMed ID: 27347396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring drug promiscuity over time.
    Hu Y; Bajorath J
    F1000Res; 2014; 3():218. PubMed ID: 25352982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Promiscuity Cliffs Using Machine Learning.
    Blaschke T; Feldmann C; Bajorath J
    Mol Inform; 2021 Jan; 40(1):e2000196. PubMed ID: 32881355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying the tendency of therapeutic target proteins to bind promiscuous or selective compounds.
    Hu Y; Bajorath J
    PLoS One; 2015; 10(5):e0126838. PubMed ID: 26000736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth of ligand-target interaction data in ChEMBL is associated with increasing and activity measurement-dependent compound promiscuity.
    Hu Y; Bajorath J
    J Chem Inf Model; 2012 Oct; 52(10):2550-8. PubMed ID: 22978710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
    Dimova D; Hu Y; Bajorath J
    J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compound promiscuity: what can we learn from current data?
    Hu Y; Bajorath J
    Drug Discov Today; 2013 Jul; 18(13-14):644-50. PubMed ID: 23524195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entering the 'big data' era in medicinal chemistry: molecular promiscuity analysis revisited.
    Hu Y; Bajorath J
    Future Sci OA; 2017 Jun; 3(2):FSO179. PubMed ID: 28670471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of search parameters and criteria on compound selection, promiscuity, and pan assay interference characteristics.
    Hu Y; Bajorath J
    J Chem Inf Model; 2014 Nov; 54(11):3056-66. PubMed ID: 25329977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution view of compound promiscuity.
    Hu Y; Bajorath J
    F1000Res; 2013; 2():144. PubMed ID: 24358872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying Promiscuous Compounds with Activity against Different Target Classes.
    Feldmann C; Miljković F; Yonchev D; Bajorath J
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31752252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity.
    Feldmann C; Yonchev D; Stumpfe D; Bajorath J
    Mol Pharm; 2020 Dec; 17(12):4652-4666. PubMed ID: 33151084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring compound promiscuity patterns and multi-target activity spaces.
    Hu Y; Gupta-Ostermann D; Bajorath J
    Comput Struct Biotechnol J; 2014; 9():e201401003. PubMed ID: 24688751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Impact: The Role of Promiscuous Binding Sites in Polypharmacology.
    Cerisier N; Petitjean M; Regad L; Bayard Q; Réau M; Badel A; Camproux AC
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31295958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Molecular Promiscuity Evaluation Through Assay Profiles.
    Avram S; Curpan R; Bora A; Neanu C; Halip L
    Pharm Res; 2018 Oct; 35(11):240. PubMed ID: 30338400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.